Does State Medicaid Cover NMN or NR (Nicotinamide Mononucleotide/Riboside)?

Why Medicaid Does Not Cover NMN or NR

The short answer is regulatory classification. Medicaid formularies include FDA-approved prescription drugs and, in some states, a narrow set of over-the-counter medications. NMN and NR do not qualify under either category, which makes formulary inclusion impossible under current federal Medicaid rules.

The Medicaid Drug Rebate Program, established under the Omnibus Budget Reconciliation Act of 1990, requires manufacturers to sign rebate agreements with CMS before a product can appear on any state Medicaid formulary. Dietary supplement manufacturers have no mechanism to enter these agreements because the FDA regulates supplements under the Dietary Supplement Health and Education Act (DSHEA) of 1994, not the Federal Food, Drug, and Cosmetic Act's drug provisions. This distinction is not a technicality. It is the single structural reason NMN and NR cannot be covered.

NR is marketed under brand names like Niagen and Tru Niagen as a dietary supplement with self-affirmed GRAS (Generally Recognized as Safe) status. NMN's regulatory path has been more complicated. In late 2022, the FDA questioned whether NMN could continue to be sold as a supplement after Metro International Biotech filed an investigational new drug (IND) application for a proprietary NMN formulation. That dispute remains unresolved as of mid-2026, but it has not moved NMN any closer to prescription drug status or Medicaid eligibility.

The Difference Between NMN, NR, and Prescription Niacin

All three compounds feed into the same metabolic endpoint, but their regulatory and coverage profiles differ sharply. NMN and NR are NAD+ precursors sold as supplements. Prescription niacin (nicotinic acid) is an FDA-approved drug with established Medicaid coverage for dyslipidemia.

Niacin raises NAD+ levels through a different biosynthetic route. A 2004 study published in the Journal of Biological Chemistry demonstrated that all three B3 vitamers (nicotinic acid, nicotinamide, and nicotinamide riboside) are converted to NAD+ through distinct enzymatic pathways. NMN enters the salvage pathway via the enzyme NMNAT, while NR first converts to NMN through nicotinamide riboside kinases (NRK1/NRK2) before following the same route [1].

The practical difference for Medicaid beneficiaries: prescription extended-release niacin (Niaspan) or immediate-release niacin carries a Medicaid-covered indication for lipid management, and it does raise NAD+ levels. It is not marketed or dosed as a longevity supplement, but it is the only NAD pathway compound accessible through Medicaid. Typical Medicaid copays for generic niacin range from $1 to $3 per month, compared with $50 to $120 monthly for retail NMN or NR products.

What the Human Evidence Actually Shows for NMN and NR

Clinical data on NMN in humans remains thin. The most cited trial is Yoshino et al. (2021), published in Science, which enrolled 25 postmenopausal women with prediabetes and obesity. Participants received 250 mg of NMN daily for 10 weeks. The study found that NMN improved skeletal muscle insulin signaling and insulin sensitivity as measured by hyperinsulinemic-euglycemic clamp, but it did not produce statistically significant changes in body weight, blood pressure, or plasma lipids [2].

That is a 25-person mechanistic study, not the kind of large randomized controlled trial (RCT) that supports FDA approval or formulary placement.

NR has a somewhat larger evidence base. A randomized, double-blind, placebo-controlled crossover trial by Martens et al. (2018) enrolled 24 lean, healthy middle-aged and older adults. Participants took 1 to 000 mg of NR daily (as Niagen) for 6 weeks. NR successfully raised whole-blood NAD+ by approximately 60%, and the researchers observed a trend toward lower systolic blood pressure (reduction of 2.3 mmHg) and reduced aortic stiffness, though neither reached the primary endpoint threshold for significance [3].

A larger trial by Elhassan et al. (2019) confirmed that NR supplementation (1 to 000 mg/day for 21 days) raises NAD+ metabolites in skeletal muscle of older men, with detectable shifts in the muscle transcriptome and anti-inflammatory cytokine profiles [4]. Sample size was 12 participants. These are proof-of-concept studies, not registration-quality trials. No NMN or NR trial has enrolled more than 100 participants in a single arm with clinical endpoints relevant to an FDA-approvable indication.

Dr. Charles Brenner, the biochemist who first described the NR kinase pathway, has stated publicly: "NAD precursor supplementation has biological activity in humans, but we are years away from having the clinical trial data needed to support a drug indication." That assessment aligns with the FDA's current posture.

Prior Authorization, Step Therapy, and Formulary Tiers: Why None Apply

Medicaid prior authorization (PA) and step therapy requirements exist only for drugs listed on a state's preferred drug list (PDL) or formulary. Because NMN and NR are not on any state Medicaid formulary, there is no PA form to submit, no step therapy protocol to follow, and no tier assignment.

This is a common source of confusion. Beneficiaries sometimes call their Medicaid managed care organization (MCO) and ask how to get NMN authorized. The MCO cannot process the request because the national drug code (NDC) for a dietary supplement does not map to a covered therapeutic class in the MCO's pharmacy benefit management system. The call typically ends with the MCO representative explaining that the product is not in their system, which beneficiaries sometimes misinterpret as a denial. It is not a denial. It is an absence of coverage eligibility.

For context, even FDA-approved drugs with longevity-adjacent marketing face steep Medicaid access barriers. Fewer than half of state Medicaid programs cover GLP-1 receptor agonists for obesity (as distinct from type 2 diabetes), and those are drugs with phase III trial portfolios involving tens of thousands of participants [5]. A supplement with fewer than 200 total human study participants across all trials has no path to that level of coverage.

Can You Appeal a Medicaid Denial for NMN or NR?

Technically, every Medicaid beneficiary has the right to a fair hearing under 42 U.S.C. § 1396a(a)(3). But an appeal requires a prior adverse determination. Because NMN and NR claims cannot be submitted through the pharmacy benefit, there is no adverse determination to appeal in most cases.

If a clinician submitted a medical claim (not a pharmacy claim) for an NMN-related service and the state Medicaid agency denied it, a fair hearing could be requested. The beneficiary would need to demonstrate medical necessity for a specific FDA-approved indication. Since NMN and NR lack any FDA-approved indication, this argument has no regulatory footing.

Some legal aid organizations have helped Medicaid beneficiaries appeal denials for off-label uses of FDA-approved drugs by citing the Social Security Act Section 1927(d)(1)(B), which limits the exclusions states can apply to covered outpatient drugs. That provision does not apply to supplements. A fair-hearing request for NMN or NR coverage would almost certainly fail at the administrative law judge (ALJ) level.

Manufacturer Savings Cards and Medicaid: The Legal Barrier

Federal anti-kickback statute (AKS) provisions under the OIG Special Advisory Bulletin prohibit pharmaceutical manufacturers from offering copay assistance to Medicaid beneficiaries. This rule applies to prescription drugs. NMN and NR are not prescription drugs, so the AKS question is moot: there is no manufacturer savings card to restrict, because there is no covered prescription to discount.

Some NMN and NR supplement companies offer subscription discounts, loyalty pricing, or bulk purchase options through direct-to-consumer channels. These discounts are available to anyone regardless of insurance status. A Medicaid beneficiary can purchase NMN or NR at retail or online just as any consumer would. Typical monthly costs range from $40 for lower-dose NR (300 mg/day) to $120 or more for higher-dose NMN (500 to 1 to 000 mg/day) from tested brands.

States with Broader Supplement or Integrative Coverage

A handful of state Medicaid programs have experimented with covering limited categories of non-prescription products. Oregon's Medicaid program (Oregon Health Plan) has historically covered some naturopathic services. Vermont and a few other states have piloted coverage for specific over-the-counter items like prenatal vitamins, smoking cessation aids, and certain minerals.

None of these pilot programs have included NMN or NR. The Centers for Medicare and Medicaid Services (CMS) State Medicaid Director Letter from January 2023 clarified that states may cover certain OTC drugs that have NDCs and participate in the Medicaid Drug Rebate Program. Dietary supplements marketed under DSHEA remain excluded from this pathway [6].

The 2023 Consolidated Appropriations Act expanded the definition of "covered outpatient drug" to include certain OTC products, but only those with approved NDCs through the drug rebate program. NMN and NR manufacturers have not entered the rebate program and, as supplement makers, cannot do so under existing law.

How to Access NMN or NR on a Limited Budget

Medicaid beneficiaries who want to try NMN or NR have several options outside insurance coverage. Online retailers offer NMN at $30 to $60 per month for doses of 250 to 500 mg/day. NR (as Niagen/Tru Niagen) typically costs $40 to $50 per month at the 300 mg/day dose. Prices have fallen roughly 40% since 2022 due to increased manufacturing competition from multiple suppliers.

Third-party testing matters here. Because supplements are not subject to FDA pre-market approval, product quality varies significantly. Organizations like NSF International and the United States Pharmacopeia (USP) offer voluntary certification programs. Choosing a product with NSF or USP verification reduces the risk of underdosed or contaminated supplements.

For Medicaid beneficiaries specifically interested in raising NAD+ levels, discussing prescription niacin with a primary care provider is a covered alternative. A 2020 systematic review of 12 clinical trials found that nicotinamide (another B3 vitamer) at doses of 1 to 3 grams daily raised NAD+ levels by 40 to 100% in multiple tissue compartments, with flushing-free formulations available as prescription or OTC products [7]. Generic immediate-release niacin is available for under $5 per month at most pharmacies.

What Would Need to Change for Medicaid Coverage

NMN or NR would need to clear three hurdles before any state Medicaid formulary could include them. First, a manufacturer would need to conduct phase III randomized controlled trials with primary clinical endpoints (not biomarker surrogates like blood NAD+ levels) and obtain FDA approval for a specific disease indication. Second, the manufacturer would need to sign a Medicaid Drug Rebate Agreement with CMS, committing to minimum rebate percentages. Third, a state pharmacy and therapeutics (P&T) committee would need to add the drug to the preferred drug list after reviewing comparative effectiveness data.

Each of these steps typically takes 2 to 5 years. No NMN or NR manufacturer has publicly announced a phase III program with clinical endpoints as of May 2026. Metro International Biotech's IND for MIB-626 (a crystalline form of NMN) represents the most advanced pharmaceutical development program, but published data from their phase I trial covered only safety and pharmacokinetics in 40 healthy adults, not efficacy [8].

The earliest realistic timeline for FDA approval of an NMN- or NR-based prescription drug, if a phase III program launched today, would be 2030 or later. Medicaid coverage would follow 6 to 18 months after approval, depending on state P&T review cycles.

Medicaid beneficiaries considering NMN or NR should discuss the decision with their provider, confirm the product carries third-party purity testing (NSF or USP verified), and start at the lowest studied dose: 250 mg/day for NMN or 300 mg/day for NR, taken with food in the morning.